[1] Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology, 2017, 66(5):1486-1501. [2]Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65(8):1359-1368. [3] 徐亮, 钟燕, 苏淑婷, 等. 反应性氧化物、脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究. 中华肝脏病杂志, 2020, 28(3): 247-253. [4] Di N, Zhou X, Chen Y, et al. Could semiquantitative analysis of real-time ultrasound elastography distinguish more liver parenchyma alterations of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome?. Arch Endocrinol Metab, 2019, 63(2):128-136. [5] Zhang S, Gu Y, Wang L, et al. Association between dietary raw garlic intake and newly diagnosed nonalcoholic fatty liver disease: a population-based study. Eur J Endocrinol, 2019, 181(6):591-602. [6] Zheng J, Zhou Y, Zhang K, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord, 2018, 18(1):147. [7] Chen LZ, Xin YN, Geng N, et al. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol, 2015, 21(3):794-802. [8] Qin S, Wang S, Wang X, et al. Liver stiffness assessed by transient elastographyas a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease. J Clin Lab Anal, 2019, 33(2):e22657. [9] 瞿欢佳, 王磊, 金沛桦, 等. 氢质子磁共振波谱在脂肪性肝病肝脏甘油三酯含量测定中的价值和其影响因素. 中华肝脏病杂志, 2017, 25(11): 858-863. [10] Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF,and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol, 2019, 70(1):133-141. [11] Park CC, Hooker C, Hooker JC, et al. Assessment of a high-SNR chemical-shift-encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the low-fat range. J Magn Reson Imaging, 2019, 49(1):229-238. [12] Wang JH, Ou HY, Yen YH, et al. Usefulness of controlled attenuation parameter in detecting and monitoring hepatic steatosis with MRI-PDFF as reference. Dig Dis Sci, 2020, 65(5):1512-1519. [13] Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 2019, 69(6):2414-2426. [14] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华糖尿病杂志, 2010, 2(1): 15-19. [15] Liu J, Wang T, He K, et al. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. Eur Rev Med Pharmacol Sci, 2019,23(18):8158-8167. [16] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018年版). 实用肝脏病杂志, 2018, 21(2):177-186. [17] Liao R, Fu YP,Wang T, et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:a retrospective cohort study at two centers in China. Oncotarget, 2017, 8(1): 1774-1781. [18] Tang A,Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology, 2013, 267(2): 422431. [19] Wildman-Tobriner B, Middleton MM, Moylan CA, et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Gastroenterology, 2018, 155(5):1428-1435.e2. [20] Gu J, Liu S, Du S, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol, 2019, 29(7):3564-3573. [21] Schwimmer JB, Middleton MS, Behling C, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology, 2015, 61(6):1887-1895. [22] Middleton MS, Van Natta ML, Heba ER, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67(3):858-872. [23] Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 2018, 67(4):1348-1359. |